Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dostarlimab: First Approval.

Literature DB >> 34106455

Dostarlimab: First Approval.

Abstract

Dostarlimab (Jemperli™; GlaxoSmithKline) is a humanized monoclonal antibody programmed death-1 (PD-1) receptor antagonist being developed for the treatment of various cancers. Based on preliminary results from the GARNET trial dostarlimab has recently been approved in the EU and USA for the treatment of adult patients with mismatch repair deficient recurrent or advanced endometrial cancer. This article summarizes the milestones in the development of dostarlimab leading to these first approvals.

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 34106455 DOI： 10.1007/s40265-021-01539-5

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

1 in total

1. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.

Authors: Ajay K Nooka; Katja Weisel; Niels Wcj van de Donk; David Routledge; Paula Rodriguez Otero; Kevin Song; Hang Quach; Natalie Callander; Monique C Minnema; Suzanne Trudel; Nicola A Jackson; Christoph M Ahlers; Ellie Im; Shinta Cheng; L Smith; Nahi Hareth; Geraldine Ferron-Brady; Maria Brouch; Rocio Montes de Oca; Sofia Paul; Beata Holkova; Ira Gupta; Brandon E Kremer; Paul Richardson
Journal: Future Oncol Date: 2021-03-08 Impact factor: 3.404

1 in total

13 in total

Review 1. Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Authors: Dan-Dan Shen; Ya-Ping Bi; Jing-Ru Pang; Li-Juan Zhao; Long-Fei Zhao; Ya Gao; Bo Wang; Hui-Min Liu; Ying Liu; Ning Wang; Yi-Chao Zheng; Hong-Min Liu
Journal: Cell Mol Life Sci Date: 2022-07-11 Impact factor: 9.207

2. Dostarlimab, a boon or a healthcare burden- too early to acertain!

Authors: Nabeela Fatima; Nashra Tabbasum; Kiranmai Mandava
Journal: Ann Med Surg (Lond) Date: 2022-06-24

Review 3. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.

Authors: Gizem Kayki-Mutlu; Zinnet Sevval Aksoyalp; Leszek Wojnowski; Martin C Michel
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2022-05-11 Impact factor: 3.195

Review 4. Hedgehog Pathway Inhibitors against Tumor Microenvironment.

Authors: Silpa Gampala; Jer-Yen Yang
Journal: Cells Date: 2021-11-12 Impact factor: 6.600

5. Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment.

Authors: Allison W Kurian; Paul Abrahamse; Ann S Hamilton; Jennifer L Caswell-Jin; Scarlett L Gomez; Timothy J Hofer; Kevin C Ward; Steven J Katz
Journal: JNCI Cancer Spectr Date: 2022-07-01

6. Jemperli (Dostarlimab-gxly): An unprecedented cancer trial.

Authors: Eman Ali; Aayat Ellahi; Mariam Adil; Asim Shaikh; Zunera Huda
Journal: Ann Med Surg (Lond) Date: 2022-06-25

Review 7. Dostarlimab: A Review.

Authors: Bárbara Costa; Nuno Vale
Journal: Biomolecules Date: 2022-07-26

Review 8. Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment.

Authors: Vanshikha Singh; Afsana Sheikh; Mohammed A S Abourehab; Prashant Kesharwani
Journal: Biosensors (Basel) Date: 2022-08-08

9. Dostarlimab: A breakthrough in the field of oncology.

Authors: Hassan Ul Hussain; Muhammad Husban Burney; Syeda Tayyaba Rehan; Mohammad Mehedi Hasan
Journal: Ann Med Surg (Lond) Date: 2022-07-05

Review 10. Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider.

Authors: Brittany A Klein; Muhammad Ali Shazib; Alessandro Villa; Fábio de Abreu Alves; Piamkamon Vacharotayangul; Stephen Sonis; Stefano Fedele; Nathaniel S Treister
Journal: Front Oral Health Date: 2022-08-11